Marie Bosslett, Assistant Editor

Indomo's ClearPen could revolutionize acne treatment with at-home microneedle injections, offering instant access to effective corticosteroid therapy for inflammatory lesions.

Chava Wald shares her inspiring journey with AD, advocating for patient empowerment and compassionate care during Eczema Awareness Month.

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, outline their long-term vision for the National Dermatology Leadership Summit, promoting collaboration and advocacy.

Incyte reveals promising TRuE-AD4 trial results for ruxolitinib cream, showcasing its effectiveness and safety for adults with moderate atopic dermatitis.

At Fall Clinical, new findings from the ENCOMPASS study revealed significant unmet needs in psoriasis care, highlighting a strong preference for effective oral therapies among patients and providers.

Quoin Pharmaceuticals' QRX003 granted FDA Orphan Drug Designation, advancing treatment for Netherton Syndrome, a rare dermatological disease.

Discover how the National Dermatology Leadership Summit will unite PAs and NPs to enhance collaboration, education, and advocacy in dermatology.

Bristol Myers Squibb reveals promising data on deucravacitinib's efficacy for psoriatic arthritis and systemic lupus erythematosus, highlighting its potential as a new treatment option.

New data from Johnson & Johnson's ICONIC-TOTAL study reveals icotrokinra's promising long-term efficacy and safety for treating challenging plaque psoriasis.

AVAVA receives FDA clearance for wrinkle treatment, showcasing significant results and high patient satisfaction with its innovative Focal Point Technology.

Explore real-world strategies with Leigh Ann Pansch, MSN, FNP-BC, DCNP, for managing psoriasis, emphasizing patient-centered care, and implementing individualized biologic treatment approaches.

Medicus Pharma has initiated a phase 2 trial in the United Arab Emirates (UAE), exploring noninvasive treatment for basal cell carcinoma (BCC) using innovative microneedle technology.

Discover non-clinical career paths for PAs and NPs at the 2025 PDPA Keystone Conference, featuring insights from Shanna Miranti, MPAS, PA-C, and Lauren Miller, PA-C.

CO₂ laser treatment significantly enhances quality of life for hidradenitis suppurativa patients, showing promising outcomes in a large prospective study.

Cemiplimab is revolutionizing treatment for high-risk cutaneous squamous cell carcinoma, bridging gaps in care and improving patient outcomes.

Azitra reveals promising preclinical results for ATR-01, a novel treatment targeting ichthyosis vulgaris, paving the way for future clinical trials.

Experts discuss the OX40 pathway's potential to transform atopic dermatitis treatment, addressing unmet needs and promising new therapies for better patient outcomes.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about the approval of cemiplimab as adjuvant immunotherapy for high-risk CSCC, FDA safety communication on RF microneedling, dermatologists' role in breast cancer awareness, and more.

This review of the latest dermatologic studies highlights new research on hidradenitis suppurativa, including associated pediatric comorbidities, CO2 laser treatment, impact on sexual health, and more.

Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.

FDA warns of serious risks associated with RF microneedling, urging patient education and careful provider training to ensure safety in aesthetic dermatology.

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Kachiu Lee, MD, MPH, FAAD, shares insights on aesthetic dermatology at the 2025 PDPA Keystone, emphasizing trust and communication over technology for optimal results.

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

Topical dapsone shows promise in treating various mucocutaneous diseases, including rosacea and neutrophilic dermatoses, with a favorable safety profile.

Regeneron's cemiplimab-rwlc gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, significantly improving disease-free survival.

Explore the latest advancements in retinoid technology with AlphaRet, enhancing skin tolerability and efficacy for diverse patient needs.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!